Friday, June 30, 2023
SK bioscience and Sanofi announced positive results from Phase II clinical trials of their 21-valent pneumococcal conjugate vaccine candidate, known as GBP410 or SP0202.
GBP410 is an innovative pneumococcal conjugate vaccine that has been collaboratively developed by SK bioscience and Sanofi. This vaccine is designed to combat pneumococcal diseases, including pneumonia and invasive pneumococcal disease, which are caused by the bacterium Streptococcus pneumoniae. GBP410 works by combining specific proteins with the polysaccharide capsule of the bacteria, thereby enhancing the immune response against this pathogen.
The significance of GBP410 lies in its coverage of 21 serotypes, which is expected to offer broader protection compared to existing pneumococcal conjugate vaccines.
The Phase II study enrolled 140 toddlers aged 12 to 15 months and 712 infants aged 42 to 89 days.
The results of the study demonstrated comparable immunogenicity of GBP410 when compared to the control vaccine. Immunogenicity refers to the ability of a vaccine to induce an immune response. The primary vaccination was administered at 2, 4, and 6 months of age, followed by a booster vaccination for children aged 12 to 15 months.
These positive Phase II results suggest that GBP410 has the potential to be an effective and safe pneumococcal conjugate vaccine with broader serotype coverage.
